Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 3/2017

28.10.2016 | Original Article

Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients

verfasst von: Marianna Pelloni, Giulia Coltrinari, Donatella Paoli, Francesco Pallotti, Francesco Lombardo, Andrea Lenzi, Loredana Gandini

Erschienen in: Endocrine | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Various microRNAs from the miR-371-3 and miR-302a–d clusters have recently been proposed as markers for testicular germ cell tumours. Upregulation of these miRNAs has been found in both the tissue and serum of testicular cancer patients, but they have never been studied in human seminal plasma. The aim of this study was, therefore, to assess the differences in the expression of miR-371-3 and miR-302a–d between the seminal plasma and serum of testicular cancer patients, and to identify new potential testicular cancer markers in seminal plasma. We investigated the serum and seminal plasma of 28 pre-orchiectomy patients subsequently diagnosed with testicular cancer, the seminal plasma of another 20 patients 30 days post-orchiectomy and a control group consisting of 28 cancer-free subjects attending our centre for an andrological check-up. Serum microRNA expression was analysed using RT-qPCR. TaqMan Array Card 3.0 platform was used for microRNA profiling in the seminal plasma of cancer patients. Results for both miR-371-3 and the miR-302 cluster in the serum of testicular cancer patients were in line with literature reports, while miR-371and miR-372 expression in seminal plasma showed the opposite trend to serum. On array analysis, 37 miRNAs were differentially expressed in the seminal plasma of cancer patients, and the upregulated miR-142 and the downregulated miR-34b were validated using RT-qPCR. Our study investigated the expression of miRNAs in the seminal plasma of patients with testicular cancer for the first time. Unlike in serum, miR-371-3 cannot be considered as markers in seminal plasma, whereas miR-142 levels in seminal plasma may be a potential marker for testicular cancer.
Literatur
1.
J.W. Oosterhuis, L.H. Looijenga, Testicular germ-cell tumours in a broader perspective. Nat. Rev. Cancer. 5, 210–22 (2005)CrossRefPubMed
2.
C. Bosetti, P. Bertuccio, L. Chatenoud, E. Negri, C. La Vecchia, F. Levi, Trends in mortality from urologic cancers in Europe, 1970–2008. Eur. Urol. 60, 1–15 (2011)CrossRefPubMed
3.
F. Bray, L. Richiardi, A. Ekbom, D. Forman, E. Pukkala, M. Cuninkova, H. Møller, Do testicular seminoma and nonseminoma share the same etiology? Evidence from an age-period-cohort analysis of incidence trends in eight European countries. Cancer. Epidemiol. Biomark. Prev. 15, 652–658 (2006)CrossRef
4.
J. Beyer, P. Albers, R. Altena, J. Aparicio, C. Bokemeyer, J. Busch, R. Cathomas, E. Cavallin-Stahl, N.W. Clarke, J. Claßen, G. Cohn-Cedermark, A.A. Dahl, G. Daugaard, U. De Giorgi, M. De Santis, M. De Wit, R. De Wit, K.P. Dieckmann, M. Fenner, K. Fizazi, A. Flechon, S.D. Fossa, J.R. Germá Lluch, J.A. Gietema, S. Gillessen, A. Giwercman, J.T. Hartmann, A. Heidenreich, M. Hentrich, F. Honecker, A. Horwich, R.A. Huddart, S. Kliesch, C. Kollmannsberger, S. Krege, M.P. Laguna, L.H.J. Looijenga, J.P. Lorch ALotz, F. Mayer, A. Necchi, N. Nicolai, J. Nuver, K. Oechsle, J. Oldenburg, J.W. Oosterhuis, T. Powles, E. Rajpert-De Meyts, O. Rick, G. Rosti, R. Salvioni, M. Schrader, S. Schweyer, F. Sedlmayer, A. Sohaib, R. Souchon, T. Tandstad, C. Winter, C. Wittekind, Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann. Oncol. 24, 878–888 (2013)CrossRefPubMed
5.
H.S. Haugnes, G.J. Bosl, H. Boer, J.A. Gietema, M. Brydøy, J. Oldenburg, A.A. Dahl, R.M. Bremnes, S.D. Fosså, Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J. Clin. Oncol. 20, 3752–3763 (2012)CrossRef
6.
A. Horwich, J. Shipley, R. Huddart, Testicular germ cell cancer. Lancet. 29, 1398 (2006)
7.
L.J. Barlow, G.M. Badalato, J.M. McKiernan, Serum tumor markers in the evaluation of male germ cell tumors. Nat. Rev. Urol. 7, 610–617 (2010)CrossRefPubMed
8.
V.N. Kim, J. Han, M.C. Siomi, Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell. Biol. 10, 126–139 (2009)CrossRefPubMed
9.
E. Rajpert-De Meyts, J.E. Nielsen, N.E. Skakkebaek, K. Almstrup, Diagnostic markers for germ cell neoplasms: from placental-like alkaline phosphatase to micro-RNAs. Folia Histochem. Cytobiol. 53, 177–188 (2015)CrossRefPubMed
10.
M.A. Rijlaarsdam, T. van Agthoven, A.J. Gillis, S. Patel, K. Hayashibara, K.Y. Lee, L.H. Looijenga, Identification of known and novel germ cell cancer-specific (embryonic) miRs in serum by high-throughput profiling. Andrology 3, 85–91 (2015)CrossRef
11.
K.P. Dieckmann, M. Spiekermann, T. Balks, I. Flor, T. Löning, J. Bullerdiek, G. Belge, MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br. J. Cancer. 6, 1754–1760 (2012)CrossRef
12.
A.J. Gillis, H.J. Stoop, R. Hersmus, J.W. Oosterhuis, Y. Sun, C. Chen, S. Guenther, J. Sherlock, I. Veltman, J. Baeten, P.J. van der Spek, P. de Alarcon, L.H. Looijenga, High-throughput microRNAome analysis in human germ cell tumours. J. Pathol. 213, 319–328 (2007)CrossRefPubMed
13.
G. Belge, K.P. Dieckmann, M. Spiekermann, T. Balks, J. Bullerdiek, Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumors? Eur. Urol. 61, 1068–1069 (2012)CrossRefPubMed
14.
I. Syring, J. Bartels, S. Holdenrieder, G. Kristiansen, S.C. Müller, J. Ellinger, Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. J. Urol. 193, 331–337 (2015)CrossRefPubMed
15.
C. Wang, C. Yang, X. Chen, B. Yao, C. Yang, C. Zhu, L. Li, J. Wang, X. Li, Y. Shao, Y. Liu, J. Ji, J. Zhang, K. Zen, C.Y. Zhang, C. Zhang, Altered profile of seminal plasma microRNAs in the molecular diagnosis of male infertility. Clin. Chem. 57, 1722–1731 (2011)CrossRef
16.
W. Wu, Z. Hu, Y. Qin, J. Dong, J. Dai, C. Lu, W. Zhang, H. Shen, Y. Xia, X. Wang, Seminal plasma microRNAs: potential biomarkers for spermatogenesis status. Mol. Hum. Reprod. 18, 489–497 (2012)CrossRefPubMed
17.
S.C. McIver, S.D. Roman, B. Nixon, E.A. McLaughlin, miRNA and mammalian male germ cells. Hum. Reprod. Update 18, 44–59 (2012)CrossRefPubMed
18.
M. Abu-Halima, C. Backes, P. Leidinger, A. Keller, A.M. Lubbad, M. Hammadeh, E. Meese, MicroRNA expression profiles in human testicular tissues of infertile men with different histopathologic patterns. Fertil. Steril. 101, 78–86 (2014)CrossRefPubMed
19.
L.A. Selth, M.J. Roberts, C.W. Chow, V.R. Marshall, S.A. Doi, A.D. Vincent, L.M. Butler, M.F. Lavin, W.D. Tilley, R.A. Gardiner, Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocr. Relat. Cancer. 21, L17–21 (2014)CrossRefPubMed
20.
L.O. Reis, T.C. Pereira, I. Lopes-Cendes, U. Ferreira, MicroRNAs: a new paradigm on molecular urological oncology. Urology. 76, 521–527 (2010)CrossRefPubMed
21.
J.A. Weber, D.H. Baxter, S. Zhang, D.Y. Huang, K.H. Huang, M.J. Lee, D.J. Galas, K. Wang, The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733–1741 (2010)CrossRefPubMedPubMedCentral
22.
K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25, 402–8 (2001)CrossRefPubMed
23.
J. Brennecke, D.R. Hipfner, A. Stark, R.B. Russell, S.M. Cohen, Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113, 25–36 (2003)CrossRefPubMed
24.
Y.S. Lee, H.K. Kim, S. Chung, K.S. Kim, A. Dutta, Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J. Biol. Chem. 280, 16635–16641 (2005)CrossRefPubMed
25.
26.
C.Z. Chen, L. Li, H.F. Lodish, D.P. Bartel, MicroRNAs modulate hematopoietic lineage differentiation. Science 2, 83–86 (2004)CrossRef
27.
V. Ambros, MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113, 673–676 (2003)CrossRefPubMed
28.
P. Xu, S.Y. Vernooy, M. Guo, B.A. Hay, The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr. Biol. 29, 790–795 (2003)CrossRef
29.
A. Esquela-Kerscher, F.J. Slack, Oncomirs. microRNAs with a role in cancer. Nat. Rev. Cancer. 6, 259–269 (2006)CrossRefPubMed
30.
31.
M.V. Iorio, C.M. Croce, microRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. EMBO Mol. Med. 4, 143–59 (2012)CrossRefPubMedCentral
32.
L. Wang, C. Xu, Role of microRNAs in mammalian spermatogenesis and testicular germ cell tumors. Reproduction 149, R127–137 (2015)CrossRefPubMed
33.
Y. He, J. Lin, D. Kong, M. Huang, C. Xu, T.K. Kim, A. Etheridge, Y. Luo, Y. Ding, K. Wang, Current state of circulating MicroRNAs as cancer biomarkers. Clin. Chem. 61, 1138–1155 (2015)CrossRefPubMed
34.
S. Dimmeler, A.M. Zeiher, Circulating microRNAs: novel biomarkers for cardiovascular diseases? Eur. Heart J. 31, 2705–2707 (2010)CrossRefPubMed
35.
A. Zampetaki, S. Kiechl, I. Drozdov, P. Willeit, U. Mayr, M. Prokopi, A. Mayr, S. Weger, F. Oberhollenzer, E. Bonora, A. Shah, J. Willeit, M. Mayr, Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 17, 810–817 (2010)CrossRef
36.
K. Wang, S. Zhang, B. Marzolf, P. Troisch, A. Brightman, Z. Hu, L.E. Hood, D.J. Galas, Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. USA 17, 4402–4407 (2009)CrossRef
37.
J. Li, X. Liang, Z. Chen, Improving the embryo implantation via novel molecular targets. Curr. Drug. Targets. 14, 864–871 (2013)CrossRefPubMed
38.
P.M. Voorhoeve, C. le Sage, M. Schrier, A.J. Gillis, H. Stoop, R. Nagel, Y.P. Liu, J. van Duijse, J. Drost, A. Griekspoor, E. Zlotorynski, N. Yabuta, G. De Vita, H. Nojima, L.H. Looijenga, R. Agami, A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 24, 1169–1181 (2006)CrossRef
39.
R.D. Palmer, M.J. Murray, H.K. Saini, S. van Dongen, C. Abreu-Goodger, B. Muralidhar, M.R. Pett, C.M. Thornton, J.C. Nicholson, A.J. Enright, N. Coleman, Children’s cancer and leukaemia group malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 1, 2911–2923 (2010)CrossRef
40.
M.J. Murray, D.J. Halsall, C.E. Hook, D.M. Williams, J.C. Nicholson, N. Coleman, Identification of microRNAs from the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am. J. Clin. Pathol. 135, 119–125 (2011)CrossRefPubMed
41.
A.J. Gillis, M.A. Rijlaarsdam, R. Eini, L.C. Dorssers, K. Biermann, M.J. Murray, J.C. Nicholson, N. Coleman, K.P. Dieckmann, G. Belge, J. Bullerdiek, T. Xu, N. Bernard, L.H. Looijenga, Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. Mol. Oncol. 7, 1083–1092 (2013)CrossRefPubMedPubMedCentral
42.
M. Spiekermann, G. Belge, N. Winter, R. Ikogho, T. Balks, J. Bullerdiek, K.P. Dieckmann, MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker. Andrology 3, 78–84 (2015)CrossRefPubMed
43.
Y. Chu, Y. Ouyang, F. Wang, A. Zheng, L. Bai, L. Han, Y. Chen, H. Wang, MicroRNA-590 promotes cervical cancer cell growth and invasion by targeting CHL1. J. Cell. Biochem. 115, 847–853 (2014)CrossRefPubMed
44.
F. Lian, Y. Cui, C. Zhou, K. Gao, L. Wu, Identification of a plasma four-microRNA panel as potential noninvasive biomarker for osteosarcoma. PLoS One. 16, e0121499 (2015)CrossRef
45.
J.L. Park, M. Kim, K.S. Song, S.Y. Kim, Y.S. Kim, Cell-Free miR-27a, a potential diagnostic and prognostic biomarker for gastric cancer. Genom. Inform 13, 70–75 (2015)CrossRef
46.
M. Bellon, Y. Lepelletier, O. Hermine, C. Nicot, Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood. 14, 4914–4917 (2009)CrossRef
47.
A.B. Hu, M. Lenarduzzi, T. Krushel, L. Waldron, M. Pintilie, W. Shi, B. Perez-Ordonez, I. Jurisica, B. O’Sullivan, J. Waldron, P. Gullane, B. Cummings, F.F. Liu, Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin. Cancer Res. 15, 1129–1139 (2010)CrossRef
48.
R.J. Lin, D.W. Xiao, L.D. Liao, T. Chen, Z.F. Xie, W.Z. Huang, W.S. Wang, T.F. Jiang, B.L. Wu, E.M. Li, L.Y. Xu, MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma. J. Surg. Oncol. 105, 175–182 (2012)CrossRefPubMed
49.
S. Kaduthanam, S. Gade, M. Meister, J.C. Brase, M. Johannes, H. Dienemann, A. Warth, P.A. Schnabel, F.J. Herth, H. Sültmann, T. Muley, R. Kuner, Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer. 80, 223–227 (2013)CrossRefPubMed
50.
L. Wu, C. Cai, X. Wang, M. Liu, X. Li, H. Tang, MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett. 6, 1322–1330 (2011)CrossRef
51.
T. Isobe, S. Hisamori, D.J. Hogan, M. Zabala, D.G. Hendrickson, P. Dalerba, S. Cai, F. Scheeren, A.H. Kuo, S.S. Sikandar, J.S. Lam, D. Qian, F.M. Dirbas, G. Somlo, K. Lao, P.O. Brown, M.F. Clarke, Y. Shimono, miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. eLife 3, e01977 (2014)CrossRefPubMedCentral
52.
H. Liu, Y. Yang, L. Zhang, R. Liang, R.S. Ge, Y. Zhang, Q. Zhang, Q. Xiang, Y. Huang, Z. Su, Basic fibroblast growth factor promotes stem Leydig cell development and inhibits LH-stimulated androgen production by regulating microRNA expression. J. Steroid Biochem. Mol. Biol. 144, 483–491 (2014)CrossRefPubMed
53.
B. Huang, J. Zhao, Z. Lei, S. Shen, D. Li, G.X. Shen, G.M. Zhang, Z.H. Feng, miR-142-3p restricts cAMP production in CD4+ CD25- T cells and CD4+ CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep. 10, 180–185 (2009)CrossRefPubMed
54.
D.M. Stocco, X. Wang, Y. Jo, P.R. Manna, Multiple signaling pathways regulating steroidogenesis and steroidogenic acute regulatory protein expression: more complicated than we thought. Mol. Endocrinol. 19, 2647–2659 (2005)CrossRefPubMed
55.
K. Tanaka, K. Kondo, K. Kitajima, M. Muraoka, A. Nozawa, T. Hara, Tumor-suppressive function of protein-tyrosine phosphatase non-receptor type 23 in testicular germ cell tumors is lost upon overexpression of miR142-3p microRNA. J. Biol. Chem. 16, 23990–23999 (2013)CrossRef
56.
H. Hermeking, The miR-34 family in cancer and apoptosis. Cell Death Differ. 17, 193–199 (2010)CrossRefPubMed
57.
S. Majid, A.A. Dar, S. Saini, V. Shahryari, S. Arora, M.S. Zaman, I. Chang, S. Yamamura, Y. Tanaka, T. Chiyomaru, G. Deng, R. Dahiya, miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer Res. 1, 73–84 (2013)CrossRef
58.
M. Rokavek, H. Li, L. Jiang, H. Hermeking, The p53/miR-34 axis in development and disease. J. Mol. Cell Biol. 6, 214–230 (2014)CrossRef
59.
L. Smorag, Y. Zheng, J. Nolte, U. Zechner, W. Engel, D.V. Pantakani, MicroRNA signature in various cell types of mouse spermatogenesis: evidence for stage-specifically expressed miRNA-221, -203 and -34b-5p mediated spermatogenesis regulation. Biol. Cell. 104, 677–692 (2012)CrossRef
Metadaten
Titel
Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients
verfasst von
Marianna Pelloni
Giulia Coltrinari
Donatella Paoli
Francesco Pallotti
Francesco Lombardo
Andrea Lenzi
Loredana Gandini
Publikationsdatum
28.10.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1150-z

Weitere Artikel der Ausgabe 3/2017

Endocrine 3/2017 Zur Ausgabe

Review

Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review

Original Article

Increased risk for hypothyroidism after anticholinesterase pesticide poisoning: a nationwide population-based study

Endocrine Methods and Techniques

Total and free cortisol levels during 1 μg, 25 μg, and 250 μg cosyntropin stimulation tests compared to insulin tolerance test: results of a randomized, prospective, pilot study

Research Letter

Circulating neuregulin 4 concentrations in patients with newly diagnosed type 2 diabetes: a cross-sectional study

Original Article

Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection

Original Article

Sirtuins 1–7 expression in human adipose-derived stem cells from subcutaneous and visceral fat depots: influence of obesity and hypoxia

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise